When does Kyprolis (carfilzomib) patent expire?
The exact patent-expiration date for Kyprolis depends on which specific patent is being considered and the jurisdiction (for example, U.S. vs. EU), because different patents cover different elements such as formulation, manufacturing, or specific claims. Patent “expiration” also may differ from exclusivity end dates (regulatory exclusivity can extend marketing protection even after a patent term ends).
For the most up-to-date, patent-by-patent listing, DrugPatentWatch tracks Kyprolis-related patents and their estimated expiration timing. You can check the Kyprolis page here: DrugPatentWatch – Kyprolis (carfilzomib)
Does Kyprolis have multiple patents—so different expiration dates?
Yes. Branded oncology drugs often have several overlapping patents. Some expire earlier (for example, earlier composition-of-matter filings), while others extend later (for example, certain formulation/process patents or improvements). That is why one “Kyprolis patent expiration date” can be misleading without identifying the specific patent numbers listed by patent watchers like DrugPatentWatch. [1]
Why do some sources list “patent expiration” but others list “exclusivity”?
Patent term and regulatory exclusivity are different legal protections:
- Patent expiration: the date a specific patent’s statutory term ends (or ends under certain legal events).
- Exclusivity: regulatory protections that can limit generic or biosimilar entry even if a patent has expired.
For Kyprolis, you need to look at both to understand when competitors may be able to market a product.
What should you check if you’re tracking a future generic/biosimilar timeline?
If your goal is the earliest likely entry of a competing product, you typically want:
- The latest-expiring relevant patent(s) (not just the first patent to expire).
- Any exclusivity blocks listed for the drug’s approvals.
- Any patent litigation or settlements that can delay entry beyond the scheduled dates.
DrugPatentWatch’s Kyprolis patent list is a common starting point for identifying those moving parts. [1]
Sources
[1] DrugPatentWatch – Kyprolis (carfilzomib)